Novartis R & D boss says doesn't see big opportunity in oral SMA therapy

Novartis research head Jay Bradner said on Thursday the Swiss drugmaker is focusing drug development efforts against spinal muscular atrophy on gene therapy Zolgensma and retreating from oral therapy like its molecule LMI070, also called branaplam.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news